# Current Applications and Future Directions of Artificial Intelligence in Prostate Cancer Diagnosis: A Narrative Review

## TL;DR

This review explores how artificial intelligence is improving prostate cancer diagnosis through better imaging, pathology, and data integration, while highlighting challenges and future directions.

## Contribution

The paper provides a comprehensive narrative review of AI applications in prostate cancer diagnosis, emphasizing novel approaches and future research priorities.

## Key findings

- AI models for MRI can improve risk stratification and reduce unnecessary biopsies.
- Deep learning algorithms in digital pathology show high agreement with expert pathologists for Gleason grading.
- AI-powered liquid biopsy models support non-invasive risk stratification for patients with borderline PSA levels.

## Abstract

Artificial intelligence is rapidly reshaping how prostate cancer is detected and characterized. Current diagnostic tools, including prostate-specific antigen testing, digital rectal examination, and magnetic resonance imaging, can lead to missed clinically significant cancers, unnecessary biopsies, and inconsistent interpretations across clinicians and institutions. This review summarizes recent applications of artificial intelligence in five diagnostic domains: medical imaging, digital pathology, liquid biopsy, multi-omics integration, and analysis of clinical information. Across selected tasks and clinical settings, artificial intelligence methods have been reported to improve diagnostic consistency, automate time-consuming tasks such as lesion detection and tumor grading, and support non-invasive risk stratification, particularly for men with borderline test results where biopsy decisions are difficult. The review also outlines key barriers to real-world adoption, including data heterogeneity, limited interpretability, workflow integration challenges, and regulatory and ethical concerns. Future efforts should prioritize multimodal data fusion with prespecified clinical endpoints, explainable models, and large prospective multicenter validation to enable safe, standardized clinical implementation.

Prostate cancer (PCa) remains a major global health challenge, yet conventional diagnostic methods are often limited by suboptimal accuracy and efficiency. Artificial intelligence (AI) has emerged as a rapidly developing technology capable of integrating multi-source data to enhance clinical decision-making. This narrative review synthesizes current evidence regarding AI applications across key diagnostic domains, including medical imaging, digital pathology, liquid biopsy, and multi-omics integration. Findings indicate that AI models for magnetic resonance imaging (MRI) can improve risk stratification and may reduce unnecessary biopsies in some cohorts, particularly when evaluated alongside structured radiology assessment and clinical variables. In digital pathology, deep learning algorithms have shown high agreement with expert genitourinary pathologists for automated Gleason grading in controlled and externally validated settings, with potential to reduce reporting time for high-volume workflows. Additionally, AI-powered liquid biopsy models may support non-invasive risk stratification, particularly for patients with prostate-specific antigen (PSA) levels in the diagnostic gray zone, while multi-omics integration is being investigated to enhance personalized assessment. Despite advances, challenges regarding data heterogeneity, algorithm interpretability, and workflow integration persist. Future research should prioritize multimodal data fusion, explainable AI development, robust calibration and decision-analytic evaluation, and large-scale prospective validation to standardize protocols and fully realize the potential of AI in precision prostate cancer care.